Another study found that cetuximab inhibited glycolysis in cetuximab-sensitive head and neck squamous cell carcinoma (HNSCC) cells by down-regulating the expression of HIF-1α and suppressing the expression of the downstream target gene lactate dehydrogenase A (LDH-A) [133]. The gene discussed is LDHA; the disease is head and neck squamous cell carcinoma.